Incretins or anti-incretins? A new model for the entero-pancreatic axis

Hormone and Metabolic Research

Volumn 47, Issue 1, 2015, Pages 84-87

  Kamvissi, V ^a,b   Salerno, A ^c   Bornstein, S R ^a,b   Mingrone, G ^d   Rubino, F ^a,c,d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d CATHOLIC UNIVERSITY   (Italy)

Author keywords

anti incretin theory; incretins; metabolic surgery; pancreatic islets

Indexed keywords

ANTIDIABETIC AGENT; GHRELIN; GLUCAGON; GLUCOSE; INCRETIN; INSULIN;

ANTI INCRETIN THEORY; BARIATRIC SURGERY; BILIOPANCREATIC BYPASS; DIABETES MELLITUS; DIET; DUODENUM; ENERGY; GASTRIC BANDING; GASTROINTESTINAL SURGERY; GASTROINTESTINAL TRACT; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HOMEOSTASIS; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; ILEUM; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; JEJUNUM; LIVER; METABOLIC SURGERY; NEGATIVE FEEDBACK; NONHUMAN; PANCREAS; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; PRIORITY JOURNAL; REMISSION; REVIEW; ROUX Y ANASTOMOSIS; SLEEVE GASTRECTOMY; SMALL INTESTINE; SURGERY; THEORY; WEIGHT REDUCTION; ANIMAL; BIOLOGICAL MODEL; DIABETES MELLITUS, TYPE 2; INTESTINE; METABOLISM; SECRETION (PROCESS);

ANIMALS; BARIATRIC SURGERY; DIABETES MELLITUS, TYPE 2; HUMANS; INCRETINS; INSULIN; INTESTINES; MODELS, BIOLOGICAL; PANCREAS;

EID: 84920742560     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0034-1394374     Document Type: Review

References (44)

1. Bayliss W. M., Starling E. H. The mechanism of pancreatic secretion. J Physiol: 1902; 28 325 353
2. Unger R. H., Eisentraut A. M. Entero-insular axis. Arch Intern Med: 1969; 123 261 266
3. Goke B., Fehmann H. C., Schirra J., Hareter A., Goke A. The intestinal hormone glucagon-like peptide 1 (GLP-1): from experiment to the clinic. Z Gastroenterol: 1997; 35 285 294
4. Dupre J., Ross S. A., Watson D., Brown J. C. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab: 1973; 37 826 828
5. Kreymann B., Ghatei M. A., Williams G., Bloom S. R. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet: 1987; 2 1300 1304
6. Musso G., Gambino R., Cassader M. Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded? Diabetes Care: 2010; 33 2277 2284
7. Graessler J., Qin Y., Zhong H., Zhang J., Licinio J., Wong MO L., Xu A., Chavakis T., Bornstein A. B., Erhart-Bornstein M., Lamounier-Zepter V., Lohmann T., Wolf T., Bornstein S. R. Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. Pharmacogenomics J: 2013; 13 514 522
8. Hansen M., Sonne D. P., Knop F. K. Bile acid sequestrants: glucose-lowering mechanisms and efficacy in type 2 diabetes. Curr Diabetes Rep: 2014; 14 482
9. Katsuma S., Hirasawa A., Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun: 2005; 329 386 390
10. Thomas C., Gioiello A., Noriega L., SStrehle A., Oury J., Rizzo G., Macchiarulo A., Yamamoto H., Mataki C., Pruzanski M., Pellicciari M., Auwerx J., Schoonjans K. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab: 2009; 10 167 177
11. Rubino F. From bariatric to metabolic surgery: definition of a new discipline and implications for clinical practice. Curr Atherosclerosis Rep: 2013; 15 369
12. Mingrone G., Panunzi S., De Gaetano A., Guidone C., Iaconelli A., Leccesi L., Nanni G., Pomp A., Castagneto M., Ghirlanda G., Rubino F. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med: 2012; 366 1577 1585
13. Schauer P. R., Kashyap S. R., Wolski K., Brethaner S. A., Kirwan J. P., Pothier C. E., Thomas S., Abood B., Nissen S. E., Bhatt D. L. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med: 2012; 366 1567 1576
14. Pories W. J., Swanson M. S., MacDonald K. G., Long S. B., Morris P. G., Brown B. M., Barakat H. A., de Ramon R. A., Israel G., Dolezal J. M., Dohm L. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg: 1995; 222 339 350 Discussion 332-350
15. Ikramuddin S., Korner J., Lee W. J., Connenett J. E., Inabnet W. B., Billington C. J., Thomas A. J., Leslie D. B., Chong K., Jeffery R. W., Ahmed L., vella A., Chuang L-M, Bessler M., Sarr M. G., Swain J. M., laqua P., Jensen M. D., Bantle J. P. Roux-en-Y gastric bypass vs. intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA: 2013; 309 2240 2249
16. Scopinaro N., Gianetta E., Civalleri D., Bonalumi U., Bachi V. Bilio-pancreatic bypass for obesity: II. Initial experience in man. Br J Surg: 1979; 66 618 620
17. Lee W. J., Lin Y. H. Single-Anastomosis Gastric Bypass (SAGB): Appraisal of Clinical Evidence. Obes Surg: 2014; 24 1749 1756
18. Schauer P. R., Bhatt D. L., Kirwan J. P., Wolski K., Brethauer S. A., Navaneethan S. D., Aminian A., Pothier C. E., Kim ES H., Nissen S. E., Kashyap S. R. for the Stampede Investigatores. Bariatric surgery versus intensive medical therapy for diabetes - 3-year outcomes. N Engl J Med: 2014; 370 2002 2013
19. Sjostrom L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med: 2013; 273 219 234
20. Sjostrom L., Peltonen M., Jacobson P., Ahlin S., Andersson-Assarsson J., Anveden A., Bouchard C., Carlsson C., Karason K., Lönroth H., Näslund I., Sjöström E., Taube M., Wedel H., Svensson P-A, Sjöholm K., Carlsson LM S. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA: 2014; 311 2297 2304
21. Bourdages H., Goldenberg F., Nguyen P., Buchwald H. Improvement in Obesity-associated Medical Conditions following Vertical Banded Gastroplasty and Gastrointestinal Bypass. Obes Surg: 1994; 4 227 231
22. Halverson J. D., Kramer J., Cave A., Permutt A., Santiago J. Altered glucose tolerance, insulin response, and insulin sensitivity after massive weight reduction subsequent to gastric bypass. Surgery: 1982; 92 235 240
23. Salehi M., Prigeon R. L., D'Alessio D. A. Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes: 2011; 60 2308 2314
24. Malin S. K., Samat A., Wolski K., Abood B., Pothier C. E., Bhatt D. L., Nissen S., Brethauer S. A., Schauer P. R., Kirwan J. P., Kashyap S. R. Improved acylated ghrelin suppression at 2 years in obese patients with type 2 diabetes: effects of bariatric surgery vs. standard medical therapy. Int J Obes: 2014; 38 364 370
25. Madsbad S., Dirksen C., Holst J. J. Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes Endocrinol: 2014; 2 152 164
26. Rubino F., Schauer P. R., Kaplan L. M., Cummings D. E. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Ann Rev Med: 2010; 61 393 411
27. Laferrere B. Effect of gastric bypass surgery on the incretins. Diabetes Metab: 2009; 35 513 517
28. Lindqvist A., Spegel P., Ekelund M., Vaz E. G., Pierzynowski S., Gomez M. F., Mulder H., Hedenbro J., Groop L., Wierup N. Gastric bypass improves beta-cell function and increases beta-cell mass in a porcine model. Diabetes: 2014; 63 1665 1671
29. Mokadem M., Zechner J. F., Margolskee R. F., Drucker D. J., Aguirre V. Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency. Mol Metab: 2014; 3 191 201
30. Shah M., Law J. H., Micheletto F., Sathananthan M., Man C. D., Cobelli C., Rizza R. A., Camilleri M., Zinsmeister A. R., Vella A. Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass. Diabetes: 2014; 63 483 493
31. Schauer P. R., Burguera B., Ikramuddin S., Cottam D., Gourash W., Hamad G., Eid G. M., Mattar S., Ramanathan R., Barinas-Mitchel E., Rao R. H., Kuller L., Kelley D. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surgery. 2003; 238 84 85 Discussion 465-484
32. Pories W. J. Diabetes: the evolution of a new paradigm. Ann Surg: 2004; 239 12 13
33. Briatore L., Salani B., Andraghetti G., Sferrazzo E., Scopinaro N., Adami G. F., Maggi D., Cordera R. Restoration of acute insulin response in T2DM subjects 1 month after biliopancreatic diversion. Obesity (Silver Spring, Md): 2008; 16 77 81
34. Guidone C., Manco M., Valera-Mora E., Iaconelli A., Gniuli D., Mari A., Nanni G., Castagneto M., Calvani M., Migrone G. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes: 2006; 55 2025 2031
35. Bikman B. T., Zheng D., Pories W. J., Chapman W., Pender J. R., Bowden R. C., Reed M. A., Cortright R. N., Tapscott E. B., Houmard J. A., Tanner C. J., Lee J., Dohm G. L. Mechanism for improved insulin sensitivity after gastric bypass surgery. J Clin Endocrinol Metab: 2008; 93 4656 4663
36. Rubino F. Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. Diabetes Care: 2008; 31 02 S290 S296
37. Rubino F., Gagner M. Potential of surgery for curing type 2 diabetes mellitus. Ann Surg: 2002; 236 554 559
38. Rubino F., Moo T. A., Rosen D. J., Dakin G. F., Pomp A. Diabetes surgery: a new approach to an old disease. Diabetes Care: 2009; 32 02 S368 S372
39. Rubino F., R'Bibo S. L., del Genio F., Mazumdar M., McGraw T. E. Metabolic surgery: the role of the gastrointestinal tract in diabetes mellitus. Nat Rev Endocrinol: 2010; 6 102 109
40. Rubino F., Amiel S. A. Is the gut the sweet spot for the treatment of diabetes? Diabetes: 2014; 63 2225 2228
41. Salinari S., le Roux C. W., Bertuzzi A., Rubino F., Mingrone G. Duodenal-jejunal bypass and jejunectomy improve insulin sensitivity in Goto-Kakizaki diabetic rats without changes in incretins or insulin secretion. Diabetes: 2014; 63 1069 1078
42. Rubino F., Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg: 2004; 239 1 11
43. Rubino F., Forgione A., Cummings D. E., Vix M., Gnuli D., Mingrone G., Castagneto M., Marescaux J. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg: 2006; 244 741 749
44. Salinari S., Debard C., Bertuzzi A., Durand C., Zimmet P., Vidal H., Mingrone G. Jejunal proteins secreted by db/db mice or insulin-resistant humans impair the insulin signaling and determine insulin resistance. PloS One: 2013; 8 e56258.